Skip to main content
Premium Trial:

Request an Annual Quote

Sure, It's a Silly Name. But You Won't Be Laughing When You Sign a $350,000 Check

Unless you were stuck under an autoclave yesterday, you've heard that another personal genomics company, Knome, announced that it was open for business.

For the bloggers' perspective, you can check out any number of sites. Bertalan Meskó jumps in with a review of Knome's website, scientific advisors, and business model -- and concludes that skepticism reigns "as Knome doesn't say a word about how they can connect the data of whole-genome sequencing to the future of my health."

Over at VentureBeat, David Hamilton has a two-part analysis of Knome, which is essentially charging customers $350,000 to have their genome sequenced. (Sure, it's pricey. But, hey, Christmas is just around the corner.) Hamilton writes, "Don't be surprised to hear critics kvetch about 'celebrity genomics' or knock Knome for catering to the rich and famous once the word gets out." Go here for part 1 and here for part 2.

 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.